SynBioBeta Speaker
Stacie Calad-Thomson
NVIDIA
BD, Life Sciences
Stacie, a former pharma and biotech leader, recently joined NVIDIA to further enable AI adoption across healthcare and the life sciences. She also serves as the vice chair of the Alliance for Artificial Intelligence in Healthcare (AAIH). In her 13+ years at GSK, she led R&D initiatives and co-founded the ATOM consortium. More recently, she held leadership roles at AI drug discovery startups Atomwise, where she was a VP of Partnerships, and BioSymetrics, where she was the Chief Strategy Officer. Stacie holds a B. S. in chemistry from the University of California, Berkeley and a Ph. D. in organic chemistry from UC Irvine.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Stacie
This Year
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
